Skip to content

Tafluprost

    DEA Class; Rx

    Common Brand Names; Zioptan

    • Antiglaucoma, Prostaglandin Agonists

    Prostaglandin analog
    Used for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension
    May increase pigmentation of eyelashes, iris, and/or eyelid skin

    Indicated for the reduction of increased intraocular pressure in patients with open-angle glaucoma or ocular hypertension..

    • Conjunctival hyperemia (4-20%)
    • Ocular stinging (7%)
    • Ocular pruritus/allergic conjunctivitis (5%)
    • Cataract (3%)
    • Growth of eyelashes (2%)
    • Blurred vision (2%)

    Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes

    Caution with active intraocular inflammation (may exacerbate condition)

    Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema

    Pregnancy Category: C; teratogenic when administered IV in rats and rabbits

    Lactation: Unknown whether distributed in breast milk

    Adults

    1 drop/day in each affected eye.

    Geriatric

    1 drop/day in each affected eye.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Tafluprost 

    ophthalmic solution

    • 0.0015% (0.015mg/mL)